programme of industry symposia - easd … · programme of industry symposia stockholm 14 september...
Post on 17-Jun-2018
227 Views
Preview:
TRANSCRIPT
www.easd-industry.com
PROGRAMME of
INDUSTRY SYMPOSIA
STOCKHOLM14 September 201517 September 2015
on the occasion of the 51st Annual Meeting
of the European Association for the Study of Diabetes
INTERPLANmedia & service gmbh
2
CONTENT
Organised and funded by AstraZeneca
Individualised patient care in Type 2 diabetes:
Translating science to practiceSymposium on the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes
Making the right choice at the right time with our patients is key to ensuring their future wellbeing. But with the vast array of potential therapies now available, and the science behind diabetes management advancing rapidly, how can we ensure we are pursuing the optimal treatment approach with each individual?
In this symposium we will translate the science and bring our patients into focus through interactive talks, interviews, discussions and Q&A sessions with world-leading experts.
Join us to explore key questions in patient management, and share views and clinical experience with the aim of raising the standard of care for patients living with diabetes.
Join us and be part of the debate!
Monday 14 September 2015,10:30–16:30Heding Hall, Stockholmsmässan
What science can do
10:30–11:00 Welcome and introduction: why and when should we treat Type 2 diabetes? C Mathieu (Belgium), J Vora (UK)
11:00–11:30 Treatment decisions for our patients: what are the considerations? R Pratley (US)
11:30–11:55 Weight gain in the treatment of Type 2 diabetes: is it inevitable? J Wilding (UK)
11:55–12:20 The kidneys in Type 2 diabetes: challenges and opportunities? M Cooper (Australia)
12:20–12:45 Can we delay escalation to insulin therapy? T Vilsbøll (Denmark)
12:45–13:00 What steps should we take to stop progression of poor glucose control? Panel discussion led by C Mathieu (Belgium), J Vora (UK)
13:00–14:00 Lunch
14:00–14:10 Welcome back C Mathieu (Belgium), J Vora (UK)
14:10–14:40 Safety of novel therapies in Type 2 diabetes: what’s the latest? J Meier (Germany)
14:40–15:05 What is the physiological basis for combining therapies? J Holst (Denmark)
15:05–15:35 Why not combine earlier? J Seufert (Germany)
15:35–16:00 What can we expect for future management of diabetes? M Davies (UK)
16:00–16:25 How should we make the right treatment choices for our patients? Panel discussion led by C Mathieu (Belgium), J Vora (UK)
16:25–16:30 Wrap up and close C Mathieu (Belgium), J Vora (UK)
Professor Chantal MathieuUniversity of Leuven, Leuven, Belgium (Co-chair)
Professor Jiten VoraHead of External Scientific Affairs, AstraZeneca, and Professor of Endocrinology, University of Liverpool, Liverpool, UK (Co-chair)
May 2015 – ATLAS ID: 762.302,011 Expiry date: 18 September 2015
786206046-001_A4 layout_v5.indd 1 22/05/2015 15:01
3
WELCOME ADDRESS
Dear Guests,
It will be a great honour and pleasure to welcome you to the 51st EASD Annual Meeting from 14 – 18 September 2015 in Stockholm, Sweden.
For many years, an integral part of the EASD Congress has been the symposia on the occasion of our Annual Meeting which have provided state-of-the-art information on developments in diabetes care and research.These symposia offer a range of valuable information and knowledge on clinical and basic research in the field of diabetes, new and upcoming treatments and major developments in the field of diabetes and its complications.
They attract opinion leaders, academic researchers, physicians and other health care professionals and offer an excellent platform for discussion and the opportunity to learn about new research as well as the latest news and updates in the world of diabetes research and care.
Beginning on September 14 with the industry symposia, an international audience of academics, researchers and physicians from over 100 countries will descend on the Stockholmsmässan in Stockholm.
For the first time in the history of the EASD Congress, I have the pleasure to invite you to attend the industry mini symposia, which take place in the afternoon of 14 September, and the industry evening symposia, which take place directly after the EASD Scientific Programme on 17 September.
These sessions provide an outstanding forum for interaction, communication, education and collaboration and are an excellent introduction to the official EASD Scientific Programme which will begin on September 15.
On behalf of EASD and the Local Organising committee, I encourage you to actively take part in the symposia on the occasion of the Annual Meeting of the European Association for the Study of Diabetes during what promises to be an outstanding 51st EASD Annual Meeting.
I look forward to welcoming you to Stockholm.
Prof. Andrew J.M. BoultonPresident, EASD
4
CONTENTSChEDuLE ................................................................................................................................ 5hALL OvERviEW ...................................................................................................................... 6PROgRAMME Of iNDuSTRy SyMPOSiA ............................................................................7
Sanofi DiabetesDifferent patients, different needs: towards an integrated care approach in diabetes care ..........................................8Novo NordiskEvolving perspectives in treating diabetes and obesity ...............................................................................................10AstraZenecaIndividualised patient care in Type 2 diabetes: translating science to practice ...........................................................12Boehringer Ingelheim & Eli Lilly and Company Getting to the heart of Type 2 Diabetes .......................................................................................................................13Novartis PharmaceuticalsThe future of diabetes: opportunities and challenges ..................................................................................................14DexComDexcom Continuous Glucose Monitoring in 2015 – Clinical Practice, Technology Innovations and Market Access .........16Pfizer Translational Pursuits ................................................................................................................................................... 17Zydus CadilaSAROGLITAZAR – A breakthrough discovery in the management of metabolic disorders .........................................18Merck Sharp & DohmeLessons Learned from the TECOS CV Safety Trial and the Evolving Role of DPP-4 Inhibitors in the Treatment of Patients with Type 2 Diabetes .......................................................................................................19AmgenDiabetic dyslipidemia, cardiovascular disease and PCSK9 inhibition with evolocumab: 4 key questions ................20Becton Dickinson & Company Inc.Optimizing Insulin Pump Therapy: Infusion Set Failures and Silent Occlusions .........................................................22TakedaShould type 2 diabetes (T2D) management be more of a priority in post-acute coronary syndrome (ACS) patients? .... 24Roche Diabetes CareHow much can technology support Personalized Diabetes Management .................................................................26Medscape Education supported by an independent educational grant from JanssenShould SGLT2 Inhibitors Be An Integral Part of a Personalized Treatment Plan for Type 2 Diabetes? ......................28AbbottOne year with flash glucose monitoring – Perspectives from different stakeholders in diabetes care. What’s next? .......29
PROgRAMME Of iNDuSTRy MiNi SyMPOSiA ................................................................30LG Life SciencesWhat is the Optimized treatment for T2DM patients? ................................................................................................30AegerionThe Metabolic Chaos of Lipodystrophy – Finding the Order Within ..........................................................................32Eli Lilly and CompanyChallenges in Comprehensive Lipid Management .....................................................................................................33
PROgRAMME Of iNDuSTRy EvENiNg SyMPOSiA .......................................................35Novo NordiskGLP-1 receptor agonists: liraglutide 3.0 mg in weight management .........................................................................35Boehringer Ingelheim & Eli Lilly and CompanyEMPA-REG OUTCOME®: Implications for management of patients with Type 2 Diabetes ........................................36Merck Sharp & DohmeThe TECOS CV Safety Trial and the Lessons Learned for Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease .......................................................................................................................................38Eli Lilly and CompanyThe Patient in Mind: new perspectives on injectable therapy for type 2 diabetes .....................................................39
BADgES DuRiNg SyMPOSiA DAyS ...................................................................................41 iMPRiNT ...................................................................................................................................42
5
SChEDuLEMonday, 14 September 2015 Industry Symposia
09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00
Keen Hall Sanofi DiabetesPage 8
Hellerström Hall Novo NordiskPage 10
Heding Hall AstraZenecaPage 12
Peltonen-Palotie Hall
Boehringer Ingelheim & Eli Lilly and CompanyPage 13
Jacobsohn Hall NovartisPage 14
Meyer-Schwickerath Hall
DexCom Page 16
AmgenPage 20
Rahbar Hall A Zydus CadilaPage 18
Doniach Hall Merck Sharp & DohmePage 19
Rahbar Hall B PfizerPage 17
Becton Dickinson & Company, Inc.Page 22
Kimmelstiel Hall TakedaPage 24
Bouchardat Hall Roche Diabetes CarePage 26
Loubatière Hall Medscape EducationPage 28
Sterne Hall AbbottPage 29
Thursday, 17 September 2015 Industry Evening Symposia19:00 20:00 21:00
Loubatière Hall Novo NordiskPage 35
Meyer-Schwickerath Hall
Boehringer Ingelheim & Eli Lilly and Company Page 36
Kimmelstiel Hall Merck Sharp & DohmePage 38
Elite Hotel Marina Tower
Eli Lilly and CompanyPage 39
Monday, 14 September 2015 Industry Mini Symposia17:00 – 18:00
Schmidt Hall LG Life SciencesPage 30
Hodgkin Hall AegerionPage 32
Pirart Hall Eli Lilly and CompanyPage 33
Sanger Hall AstraZeneca
6
hALL OvERviEW
Sanger Hall
Schmidt Hall
Kimmelstiel Hall
Bouchardat Hall
HodgkinHall
Pirart Hall
Sterne Hall
LoubatièreHall
RahbarHall A
Peltonen-PalotieHall
Heding Hall
DoniachHall
JacobsohnHall
HellerströmHall
POSTER
EXHIBITION
Ass
oci
atio
ns’ V
illag
e
KeenHall
to First Floor
RegistrationArea
MAINENTRANCE
RahbarHall B
Meyer-Schwickerath
Hall
EXITONLY
Scientific Halls Symposia Halls Exhibition
RegistrationArea
Älvsjö Station
Programme of Industry Symposia
DIfferent PatIentS, DIfferent neeDS: towarDS an IntegrateD care aPProach
In DIabeteS care
Keen Hall09:00 – 09:10 Welcome and introduction Richard Bergenstal (USA), Lars Rydén (Sweden)
09:10 – 09:20 Different patients, different needs, different approaches Athena Philis-Tsimikas (USA)
OPTIMISING AND ADVANCING BASAL INSULIN09:20 – 09:45 The evolution of basal insulin: New insights Alice Cheng (Canada)
09:45 – 10:10 When it’s time to intensify: What are the options? Robert Henry (USA)
10:10 – 10:30 Interactive audience discussion and patient summary All
10:30 – 10:50 Break
UNDERSTANDING AND MANAGING RISK IN DIABETES CARE10:50 – 11:35 Too high or too low: The risks of hyperglycaemia vs hypoglycaemia Pratik Choudhary (UK), Silvio Inzucchi (USA)
11:35 – 12:00 Getting to the heart of the matter: Understanding cardiovascular risk in diabetes Lars Rydén (Sweden)
12:00 – 12:25 Controlling cholesterol in diabetes Bertrand Cariou (France)
12:25 – 12:45 Interactive audience discussion and patient summary All
12:45 – 13:45 Lunch
EXPANDING THE HORIZONS OF DIABETES CARE13:45 – 13:50 Overview of afternoon session Richard Bergenstal (USA), Lars Rydén (Sweden)
13:50 – 14:00 Different patients, different needs, different approaches Partha Kar (UK)
14:00 – 14:25 Beyond the prescription: Setting, achieving and maintaining target Athena Philis-Tsimikas (USA)
14:25 – 14:50 Beyond pharmacotherapy: Technologies that improve how patients interact with their disease Steve Edelman (USA)
14:50 – 15:15 Beyond the clinic: How can we connect with our patients? Partha Kar (UK)
15:15 – 15:40 Patient integrated care: Comprehensive support for better patient outcomes Richard Bergenstal (USA), Lars Rydén (Sweden)
15:40 – 16:00 Patient summary + closing remarks All
MONDAy, 14 SEPTEMBER 2015 09:00 – 16:00
8
iNDuSTRy SyMPOSiA
Organised by: Sanofi Diabetes
towards an integrated care approach in diabetes
Ima
ge
s sh
ow
n a
re m
od
els
use
d fo
r illu
stra
tive
pu
rpo
ses
on
lySA
GLB
.DIA
.15.
06.0
341
Da
te o
f pre
pa
ratio
n: J
un
e 2
015
JOIN US FOR OUR SYMPOSIUM on the occasion of the 51st EASD Annual Meeting
Keen Hall Stockholm International Fairs & Congress Center Stockholm
MONDAY 14th SEPTEMBER 2015
09.00 –16.00
09.00 –16.00 Optimizing and advancing basal insulin Understanding and managing risk in diabetes care Expanding the horizons of diabetes care
DIFFERENT PATIENTS DIFFERENT NEEDS:
Please visit us at booth B06:31, hall B for further information
103028_EASD 2015_Symposium Ad_v07b_PORTRAIT.indd 1 19/06/2015 17:11
evolvIng PerSPectIveS IntreatIng DIabeteS anD obeSIty
Hellerström HallMORNING SESSION
09:00 – 09:10 Welcome Host and chair: Bo Ahrén (Sweden)
09:10 – 09:30 Is intensive behavioural therapy enough in obesity management? Michael Lean (UK)
09:30 – 09:45 Mode of action of liraglutide 3.0 mg in weight management Niels Vrang (Denmark)
09.45 – 10:00 Focused weight management strategies – update on clinical practice Nicholas Finer (UK)
10:00 – 10:15 The SCALE phase 3a clinical trial programme – benefits on secondary outcomes Luc Van Gaal (Belgium)
10:15 – 10:45 Coffee
10:45 – 11:05 Personalising the choice of anti-obesity medication (responder analyses) Donna Ryan (USA)
11:05 – 11:20 Mechanisms in cardiovascular effects of GLP-1 Mansoor Husain (Canada)
11:20 – 11:45 Managing diabetes in special populations Melanie Davies (UK)
11:45 – 12:10 Panel discussion
12:10 – 13:10 Lunch
MONDAy, 14 SEPTEMBER 2015 09:00 – 13:10
10
iNDuSTRy SyMPOSiA
Organised by: Novo Nordisk
evolvIng PerSPectIveS IntreatIng DIabeteS anD obeSIty
Hellerström HallAFTERNOON SESSION
13:10 – 13:15 Welcome Host: Bo Ahrén (Sweden), Chair: Tina Vilsbøll (Denmark)
13:15 – 13:35 Hypoglycaemia anno 2015: what we have learned Simon Heller (UK)
13:35 – 13:55 What is new in insulin treatment? Tim Heise (Germany) and Christopher Sorli (USA)
13:55 – 14:15 A new choice for diabetes treatment – the dual approach Stephen Gough (UK)
14:15 – 14:35 The clinical potential of the dual approach John Buse (USA)
14:35 – 14:50 Panel discussion
14:50 – 15:10 Cardiovascular outcomes trials in diabetes – what have we learned and where are we heading? Marc Pfeffer (USA)
15:10 – 15:20 Closure Tina Vilsbøll (Denmark)
MONDAy, 14 SEPTEMBER 2015 13:10 – 15:20
11
iNDuSTRy SyMPOSiA
Organised by: Novo Nordisk
InDIvIDualISeD PatIent care In tyPe 2 DIabeteS: tranSlatIng ScIence to PractIce
Heding Hall10:30 – 11:00 Welcome and introduction Why and when should we treat Type 2 diabetes? Chantal Mathieu (Belgium) / Jiten Vora (UK)
11:00 – 11:30 Treatment decisions for our patients: what are the considerations? Richard Pratley (USA)
11:30 – 11:55 Weight gain in the treatment of Type 2 diabetes: is it inevitable? John Wilding (UK)
11:55 – 12:20 The kidneys in Type 2 diabetes: challenges and opportunities? Mark Cooper (Australia)
12:20 – 12:45 Can we delay escalation to insulin therapy? Tina Vilsbøll (Denmark)
12:45 – 13:00 What steps should we take to stop progression of poor glucose control? Chantal Mathieu (Belgium) / Jiten Vora (UK)
13:00 – 14:00 Lunch 14:00 – 14:10 Welcome back Chantal Mathieu (Belgium) / Jiten Vora (UK)
14:10 – 14:40 Safety of novel therapies in Type 2 diabetes: what’s the latest? Juris Meier (Germany)
14:40 – 15:05 What is the physiological basis for combining therapies? Jens Holst (Denmark)
15:05 – 15:35 Why not combine earlier? Jochen Seufert (Germany)
15:35 – 16:00 What can we expect for future management of diabetes? Melanie Davies (UK)
16:00 – 16:25 How should we make the right treatment choices for our patients? Chantal Mathieu (Belgium) / Jiten Vora (UK)
16:25 – 16:30 Wrap up and close Chantal Mathieu (Belgium) / Jiten Vora (UK)
MONDAy, 14 SEPTEMBER 2015 10:30 – 16:30
12
iNDuSTRy SyMPOSiA
Organised by: AstraZeneca
13
iNDuSTRy SyMPOSiA
gettIng to the heart of tyPe 2 DIabeteS
Peltonen-Palotie Hall14:00 – 14:05 Welcome Co-chairs: Clifford Bailey (UK) and Nikolaus Marx (Germany)
SESSION 1: THE BROKEN HEARTED – CV RISK AND T2D MANAGEMENT14:05 – 14:25 Tackling CV risk in T2D – time for a change? Kausik Ray (UK)
14:25 – 14:50 New horizons for managing CV risk with anti-hyperglycaemic agents Naveed Sattar (UK)
14:50 – 15:10 The evolving landscape of CV outcome trials in T2D Nikolaus Marx (Germany)
15:10 – 15:25 Q&A Session 1 faculty
SESSION 2: HEALING HEARTACHE – DOES EMOTIONAL ENGAGEMENT WITH BASAL
INSULIN THERAPy IMPROVE OUTCOMES?15:25 – 15:40 How successful is basal insulin therapy in clinical reality? Christophe de Block (Belgium)
15:40 – 15:55 Can the empathy of healthcare professionals increase the success of basal insulin treatment in T2D? Mark Peyrot (USA)
15:55 – 16:00 Q&A Session 2 faculty
16:00 – 16:05 Closing remarks Clifford Bailey (UK)
MONDAy, 14 SEPTEMBER 2015 14:00 – 16:05
Organised by: Boehringer Ingelheim & Eli Lilly and Company
14
iNDuSTRy SyMPOSiA
the future of DIabeteS: oPPortunItIeS anD challengeS
Jacobsohn HallChair: Anthony Barnett (UK)
Guest speaker: Sir Michael Hirst (UK)
Faculty members: Kamlesh Khunti (UK)
Mark Cooper (Australia)
Focke Ziemssen (Germany)
Matthias Blüher (Germany)
13:30 – 14:30 PART 1: The vision – opportunities and challenges
14:30 – 14:50 Refreshment break
14:50 – 17:00 PART 2: The reality - opportunities and challenges
14:50 – 15:50 Will optimised diabetes care be accessible in the future?
15:50 – 17:00 Will we be able to prevent the future?
MONDAy, 14 SEPTEMBER 2015 13:30 – 17:00
Organised by: Novartis Pharmaceuticals
Item code: GLCM/GAL/0033 | GLRET/LUC/0373 | SE1505339866 Date of preparation: May 2015. ©2015 Novartis Pharma AG, CH-4002 Basel, Switzerland
This symposium may include discussion on products and/or indications still under investigation. Physicians may only prescribe products in accordance with their prescribing information. Prescribing information differs from country to country. Please refer to your local prescribing information.
THE FUTURE OF DIABETES
A Novartis-sponsored symposium on the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes
Opportunities & challenges
14 September 2015 13:30–17:00 Jacobsohn Hall, Stockholmsmässan, Stockholm, Sweden
13:30–14:30 PART 1: The vision - opportunities and challenges
14:30–14:50 Refreshment break
14:50–17:00 PART 2: The reality - opportunities and challenges
14:50–15:50 Will optimised diabetes care be accessible in the future?
15:50–17:00 Will we be able to prevent the future?
Anthony Barnett (Chair), UKSir Michael Hirst, UKKamlesh Khunti, UKMark Cooper, AustraliaFocke Ziemssen, Germany Matthias Blüher, Germany
AgendaFaculty
Item code: GLCM/GAL/0033 | GLRET/LUC/0373 | SE1505339866 Date of preparation: May 2015. ©2015 Novartis Pharma AG, CH-4002 Basel, Switzerland
This symposium may include discussion on products and/or indications still under investigation. Physicians may only prescribe products in accordance with their prescribing information. Prescribing information differs from country to country. Please refer to your local prescribing information.
THE FUTURE OF DIABETES
A Novartis-sponsored symposium on the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes
Opportunities & challenges
14 September 2015 13:30–17:00 Jacobsohn Hall, Stockholmsmässan, Stockholm, Sweden
13:30–14:30 PART 1: The vision - opportunities and challenges
14:30–14:50 Refreshment break
14:50–17:00 PART 2: The reality - opportunities and challenges
14:50–15:50 Will optimised diabetes care be accessible in the future?
15:50–17:00 Will we be able to prevent the future?
Anthony Barnett (Chair), UKSir Michael Hirst, UKKamlesh Khunti, UKMark Cooper, AustraliaFocke Ziemssen, Germany Matthias Blüher, Germany
AgendaFaculty
Item code: GLCM/GAL/0033 | GLRET/LUC/0373 | SE1505339866 Date of preparation: May 2015. ©2015 Novartis Pharma AG, CH-4002 Basel, Switzerland
This symposium may include discussion on products and/or indications still under investigation. Physicians may only prescribe products in accordance with their prescribing information. Prescribing information differs from country to country. Please refer to your local prescribing information.
THE FUTURE OF DIABETES
A Novartis-sponsored symposium on the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes
Opportunities & challenges
14 September 2015 13:30–17:00 Jacobsohn Hall, Stockholmsmässan, Stockholm, Sweden
13:30–14:30 PART 1: The vision - opportunities and challenges
14:30–14:50 Refreshment break
14:50–17:00 PART 2: The reality - opportunities and challenges
14:50–15:50 Will optimised diabetes care be accessible in the future?
15:50–17:00 Will we be able to prevent the future?
Anthony Barnett (Chair), UKSir Michael Hirst, UKKamlesh Khunti, UKMark Cooper, AustraliaFocke Ziemssen, Germany Matthias Blüher, Germany
AgendaFaculty
Item code: GLCM/GAL/0033 | GLRET/LUC/0373 | SE1505339866 Date of preparation: May 2015. ©2015 Novartis Pharma AG, CH-4002 Basel, Switzerland
This symposium may include discussion on products and/or indications still under investigation. Physicians may only prescribe products in accordance with their prescribing information. Prescribing information differs from country to country. Please refer to your local prescribing information.
THE FUTURE OF DIABETES
A Novartis-sponsored symposium on the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes
Opportunities & challenges
14 September 2015 13:30–17:00 Jacobsohn Hall, Stockholmsmässan, Stockholm, Sweden
13:30–14:30 PART 1: The vision - opportunities and challenges
14:30–14:50 Refreshment break
14:50–17:00 PART 2: The reality - opportunities and challenges
14:50–15:50 Will optimised diabetes care be accessible in the future?
15:50–17:00 Will we be able to prevent the future?
Anthony Barnett (Chair), UKSir Michael Hirst, UKKamlesh Khunti, UKMark Cooper, AustraliaFocke Ziemssen, Germany Matthias Blüher, Germany
AgendaFaculty
Dexcom contInuouS glucoSe monItorIng In 2015 – clInIcal PractIce, technology
InnovatIonS anD market acceSS
Meyer-Schwickerath HallModerator: Peter Adolfsson (Sweden)
10:00 – 10:50 Using Dexcom CGM in Clinical Practice – Education and Medical Management Peter Adolfsson (Sweden)
10:50 – 11:40 Current and Future Dexcom CGM Technology Innovations Jake Leach (USA)
11:40 – 12:30 Continuous Glucose Monitoring – Cost Modeling and Reimbursement Claudia Graham (USA)
MONDAy, 14 SEPTEMBER 2015 10:00 – 12:30
16
iNDuSTRy SyMPOSiA
Organised by: DexCom
tranSlatIonal PurSuItS
Rahbar Hall BHost Prof. Morrie Birnbaum (USA)
CSO, Pfizer CVMED
Chair Dr Julia Brosnan (USA)
10:00 – 10:10 Welcome and Opening Julia Brosnan (USA)
10:10 – 10:40 A fine-tuned classification of diabetes – steps towards individualized medicine Leif Groop (Sweden)
10:40 – 11:20 Rare and Frequent DNA Variation and Precision Diabetic Medicine Philippe Froguel (France)
11:20 – 11:50 Building a target hypothesis: genetic associations are only the start Daniel Ziemek (Germany)
11:50 – 12:30 Diamonds in the Dirt – using human genetics to Define Biology and Guide translation in type 2 Diabetes Mark McCarthy (UK)
MONDAy, 14 SEPTEMBER 2015 10:00 – 12:30
17
iNDuSTRy SyMPOSiA
Organised by: Pfizer
18
iNDuSTRy SyMPOSiA
SaroglItaZar – a breakthrough DIScovery In the management of metabolIc DISorDerS
Rahbar Hall AChairs Banshi Saboo (India), S. K. Sharma (India)
14:30 – 14:50 Diabetic dyslipidemia & its management: Review of current therapeutic options Charles Burant (USA)
14:50 – 15:10 PPAR agonism: Role in metabolic disorders Walter Wahli (Switzerland)
15:10 – 15:30 Saroglitazar: Concept to clinic Shashank R. Joshi (India)
15:30 – 15:50 Saroglitazar: An endocrinologist’s perspective Anil Bhansali (India)
15:50 – 16:10 Saroglitazar: A cardiologist’s perspective Saumitra Ray (India)
16:10 – 16:30 Saroglitazar: NASH perspective Sujoy Ghosh (India)
16:30 – 17:00 Panel discussion
MONDAy, 14 SEPTEMBER 2015 14:30 – 17:00
Organised by: Zydus Cadila
19
iNDuSTRy SyMPOSiA
leSSonS learneD from the tecoS cv Safety trIal anD the evolvIng role of DPP-4 InhIbItorS In the
treatment of PatIentS wIth tyPe 2 DIabeteS
Doniach Hall14:30 – 14:35 Chair Welcome and Opening Remarks Co-Chairs: Rury Holman (UK), Michel Komajda (France)
14:35 – 15:05 Are we Treating Patients Based on the Evidence? Previous Cardiovascular Trials: Michel Komajda (France)
DPP-4 CV Safety Trials: Michael Nauck, (Germany)
15:05 – 15:20 Audience Vote and Discussion led by Chairmen
15:20 – 15:40 DPP-4 Inhibitors: What is the Latest Science? Carolyn Deacon (Denmark)
15:40 – 15:50 Q&A
15:50 – 16:20 Lessons Learned from the TECOS CV Safety Trial: The Role of Sitagliptin in the Treatment of Cardiovascular Patients with Type 2 Diabetes Rury Holman (UK)
16:20 – 16:30 Q&A
16:30 – 16:55 Specialty Dialogue: Treatment of Patients with Type 2 Diabetes from an Endocrinology, Nephrology and Cardiology View Faculty
16:55 – 17:00 Final Comments and Summary Chairmen: Rury Holman (UK), Michel Komajda (France)
MONDAy, 14 SEPTEMBER 2015 14:30 – 17:00
Organised by: Merck Sharp & Dohme
20
iNDuSTRy SyMPOSiA
DIabetIc DySlIPIDemIa, carDIovaScular DISeaSe anD PcSk9 InhIbItIon wIth
evolocumab: 4 key queStIonS
Meyer-Schwickerath Hall14:30 – 14:35 Welcome and introduction Marja-Riitta Taskinen (Finland)
Handrean Soran (UK)
14:35 – 15:05 Targeting dyslipidemia in diabetes, is it important? Neil Poulter (UK)
15:05 – 15:35 Patients who cannot tolerate a maximum dose of statins, what should we do? Ulrich Laufs (Germany)
15:35 – 16:05 What is PCSK9 and why should you be interested in it? John Chapman (France)
16:05 – 16:45 Debate: Is LDL-C reduction more important than glucose lowering in diabetes? For: Kausik Ray (UK)
Against: Naveed Sattar (UK)
16:45 – 17:00 Panel questions and closing remarks Marja-Riitta Taskinen (Finland)
Handrean Soran (UK)
MONDAy, 14 SEPTEMBER 2015 14:30 – 17:00
Organised by: Amgen
21
iNDuSTRy SyMPOSiA
Amgen (Europe) GmbH Dammstrasse 23
CH-6300 Zug Switzerland
© 2015 Amgen Inc. All rights reserved. EUHQ-NP-145-0615-107185 June 2015
Programme
Welcome and introduction Marja-Riitta Taskinen, Finland and Handrean Soran, UK
Targeting dyslipidemia in diabetes, is it important? Neil Poulter, UK
Patients who cannot tolerate a maximum dose of statins, what should we do now? Ulrich Laufs, Germany
What is PCSK9 and why should you be interested in it? John Chapman, France
Debate: Is LDL-C reduction more important than glucose lowering in diabetes? For: Kausik Ray, UK Against: Naveed Sattar, UK
Panel questions and closing remarks Marja-Riitta Taskinen, Finland and Handrean Soran, UK
Diabetic dyslipidemia, cardiovascular disease and PCSK9 inhibition with evolocumab: 4 key questions
refreshments will be available prior to the symposium
monday 14 September 2015, 14.30–17.00Meyer-Schwickerath Hall, Stockholmsmässan, Stockholm, Sweden
Symposium on the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes
22
iNDuSTRy SyMPOSiA
oPtImIZIng InSulIn PumP theraPy: InfuSIon Set faIlureS anD SIlent occluSIonS
Rahbar Hall B14:00 – 14:30 Registration
14:30 – 14:35 Welcome, Faculty Disclosures and Program Objectives
14:35 – 14:40 Pre-test Using Audience Response System
14:40 – 15:00 Current Perspectives on Insulin Dynamics in the Subcutaneous Space Prof. Lutz Heinemann (Germany)
15:00 – 15:30 The Science of Infusion Sets: Gaps in Clinical Evidence Dr. Bruce A. Buckingham (USA)
15:30 – 15:50 Paediatric Clinical Case Prof. Thomas Danne (Germany)
15:50 – 16:10 New Insulin Infusion Set Technology Dr. Laurence J. Hirsch (USA)
16:10 – 16:20 Toward the Artificial Pancreas: Clinical Perspectives on Opportunities and Gaps Prof. J. Hans De Vries (The Netherlands)
16:20 – 16:30 New Research: What the Future Holds Dr. Aaron Kowalski (USA)
16:30 – 16:45 Demonstrations
16:45 – 16:50 Questions & Answers
16:50 – 16:55 Post-test Using Audience Response System
16:55 – 17:00 Closing Remarks
MONDAy, 14 SEPTEMBER 2015 14:30 – 17:00
Organised by: Becton Dickinson & Company Inc.
23
iNDuSTRy SyMPOSiA
Provided by Athena Education Group, LLC
Supported by Becton, Dickinson and Company
OPTIMIZING INSULIN PUMP THERAPY Infusion Set Failures and Silent Occlusions
Register atwww.bdsympo2015.com
A symposium on the occasion of the 51st EASD Annual Meeting
MONDAY, 14 SEPTEMBER 201514:30–17:00Rahbar Hall BStockholmsmässan Stockholm, Sweden
EDUCATIONAL OBJECTIVESAfter participating in the symposium, the learner will be able to:
• Recognize knowledge gaps and technical issues associated with the use of insulin infusion sets, including flow interruptions with infusion sets
• Identify strategies to improve patient and healthcare professional knowledge gaps around insulin infusion sets
• Review potential benefits of new infusion set technology in clinical care
AGENDA
For more information, please email maryjo.holden@athenaedgroup.com
14:00–14:30 Registration and Light Refreshments
14:30–14:35 Welcome, Faculty Disclosures, and Program Objectives
14:35–14:40 Pre-test Using Audience Response System
14:40–15:00 Current Perspectives on Insulin Dynamics in the Subcutaneous Space Lutz Heinemann, PhD
15:00–15:30 The Science of Infusion Sets: Gaps in Clinical Evidence Bruce A. Buckingham, MD
15:30–15:50 Paediatric Clinical Case Thomas Danne, MD
15:50–16:10 New Insulin Infusion Set Technology Laurence J. Hirsch, MD
16:10–16:20 Toward the Artificial Pancreas: Clinical Perspectives on Opportunities and Gaps J. Hans De Vries, MD, PhD
16:20–16:30 New Research: What the Future Holds Aaron Kowalski, PhD
16:30–16:45 Demonstrations
16:45–16:50 Questions & Answers
16:50–16:55 Post-test Using Audience Response System
16:55–17:00Closing Remarks
BD, BD logo and all other trademarks are property of Becton, Dickinson and Company © 2015 BD
FACULTYBruce A. Buckingham, MD (Co-Chair)Professor of Pediatrics (Endocrinology)Lucile Salter Packard Children’s HospitalLos Gatos, California, USA
J. Hans De Vries, MD, PhD (Co-Chair)Lecturer & Consultant EndocrinologistDepartment of EndocrinologyAcademic Medical CentreAmsterdam, The Netherlands
Thomas Danne, MDDiabetes Centre for Children and AdolescentsJanusz-Korczak-Allee 12Hannover, Germany
Lutz Heinemann, PhD Science & Co
Düsseldorf, Germany
Laurence J. Hirsch, MDVP Worldwide Medical Affairs Diabetes CareBecton, Dickinson and CompanyFranklin Lakes, New Jersey, USA
Aaron Kowalski, PhDChief Mission Officer and VP, ResearchJDRFNew York, New York, USA
24
iNDuSTRy SyMPOSiA
ShoulD tyPe 2 DIabeteS (t2D) management be more of a PrIorIty In PoSt-acute coronary Syn-
Drome (acS) PatIentS?
Kimmelstiel HallChair: Ele Ferrannini (Italy)
14:30 – 14:45 Welcome Ele Ferrannini (Italy)
14:45 – 15:10 The ACS patient journey: where does T2D fit in? Jean-Claude Tardif (Canada)
15:10 – 15:50 Perspectives of diabetes and cardiovascular-risk management in post-ACS T2D patients · Cardiologist’s perspective Stephen Nicholls (Australia)
· Diabetologist’s perspective Jørgen Rungby (Denmark)
15:50 – 16:30 What do we know about the safety of oral anti-diabetics in post-ACS T2D patients? Exploring evidence from recent outcomes studies Faiez Zannad (France)
16:30 – 16:55 Debating the optimal management of post-ACS T2D patients All speakers, facilitated by Ele Ferrannini
16:55 – 17:00 Conclusions and close Ele Ferrannini (Italy)
MONDAy, 14 SEPTEMBER 2015 14:30 – 17:00
Organised by: Takeda
25
iNDuSTRy SyMPOSiA
Takeda-sponsored symposium Kimmelstiel Hall,
Monday 14 September 2015; 14:30–17:00
On the occasion of the 51st Annual Meeting of the European Association for the Study of Diabetes, Stockholm, Sweden,
14 – 18 September 2015
Should type 2 diabetes (T2D) management be more of a priority in post-acute coronary
syndrome (ACS) patients?
Putting the spotlight on T2D management in post-ACS patients
Chair: Professor Ele Ferrannini
Job code: GLO/ALO/2015-00055Date of preparation: May 2015
26
iNDuSTRy SyMPOSiA
how much can technology SuPPort PerSonalIZeD DIabeteS management?
Bouchardat HallChairs: Rudy Bilous (UK) + Rolf Hinzmann (Germany)
14:30 – 14:40 Introduction
14:40 – 15:05 Surfing safely in the diabetes app tsunami Ashleigh Walker (Canada)
15:05 – 15:30 The benefits mobile health solutions like the Accu-Chek® Connect system can bring to Personalized Diabetes Management Fabio Broglio (Italy)
15:30 – 15:55 Personalized Diabetes Management today and tomorrow – options for better diabetes therapy Matthias Axel Schweitzer (Germany)
15:55 – 16:20 First results of the Accu-Chek® Insight EU Study Julia Mader (Austria)
16:20 – 16:45 CGM – Developments, indications, performance Peter Adolfsson (Sweden)
16:45 – 17:00 Discussion and closing
MONDAy, 14 SEPTEMBER 2015 14:30 – 17:00
Organised by: Roche Diabetes Care
27
iNDuSTRy SyMPOSiA
New Accu-Chek® solutions for you
The Accu-Chek® Connect diabetesmanagement system
Better connectedfor better decisions
The Accu-Chek® Insight diabetestherapy system
Designed with your patients’ lives in mind
Visit us in Hall B at stand 10.31 and fi nd out more
For more information about Accu-Chek, visit www.accu-chek.com
ACCU-CHEK, ACCU-CHEK AVIVA CONNECT, ACCU-CHEK AVIVA INSIGHT, ACCU-CHEK CONNECT and ACCU-CHEK INSIGHT are trademarks of Roche. © 2015 Roche Diabetes Care
Experience what’s possible.
www.accu-chek.comRoche Diabetes Care GmbHSandhofer Str. 116D-68305 Mannheim
N5001_EASD_ISPAD_Ad_A4_RZ.indd 1 26.06.15 10:41
28
iNDuSTRy SyMPOSiA
ShoulD Sglt2 InhIbItorS be an Integral Part of a PerSonalIZeD treatment Plan
for tyPe 2 DIabeteS?
Loubatière Hall14:30 – 14:40 Introduction and Welcome Guntram Schernthaner (Austria)
14:40 – 15:00 Updates on the Clinical and Physiologic Effects of SGLT2 Inhibition: What Have We Learned? Guntram Schernthaner (Austria)
15:00 – 15:30 Expanding Treatment Options for Glycemic Reduction in Patients with T2DM: Role of SGLT2 Inhibitors Francisco Javier Ampudia-Blasco (Spain)
15:30 – 15:55 Non-glycemic Effects of SGLT2 Inhibitors: How Novel Antihyperglycemic Therapy May Improve Patient Outcomes Ronan Roussel (France)
15:55 – 16:40 Putting It All Together: Practical Considerations for Using SGLT2 Inhibitors in the Management of Patients with T2DM John P. H. Wilding (UK)
16:40 – 16:58 Q&A Session Faculty Panel
16:58 – 17:00 Conclusions John P. H. Wilding (UK)
MONDAy, 14 SEPTEMBER 2015 14:30 – 17:00
Organised by: Medscape Education supported by an independent educational grant from Janssen
29
Sterne Hall Chair: Professor Jan Bolinder (Sweden)
14:35 – 15:05 Clinical experience with FreeStyle Libre Stig Attvall (Sweden)
15:05– 15:35 Ambulatory Glucose Profile (AGP) through the diabetes care continuum Dr. med. Oliver Schubert (Germany)
15:35 – 16:05 The Impact of AGP and FreeStyle Libre on the Patient – Clinician Dialogue in T1 Diabetes Stephen Dixon and Dr. Pratik Choudhary (UK)
16:05 – 16:35 The Impact of AGP and FreeStyle Libre on the Patient – Clinician Dialogue in T2 Diabetes Dr. med. Oliver Schubert (Germany)
16:40 – 17:00 Panel Discussion Professor Jan Bolinder and all Presenters
one year wIth flaSh glucoSe monItorIng – PerSPectIveS from DIfferent StakeholDerS
In DIabeteS care. what’S next?
MONDAy, 14 SEPTEMBER 2015 14:30 – 17:00
Organised by: Abbott
iNDuSTRy SyMPOSiA
what IS the oPtImIZeD treatment for t2Dm PatIentS?
Schmidt Hall17:00 – 17:10 Welcome Address of Chairman Prof. Moon-Kyu Lee (Korea)
17:10 – 17:30 Gemigliptin: The Optimized DPP-4 inhibitor for T2DM Patients Prof. Soo Lim (Korea)
17:30 – 17:50 The Optimal Management in T2DM Patients with Renal Impairment Prof. Eun-Jung Rhee (Korea)
17:50 – 18:00 Q&A and Closing
MONDAy, 14 SEPTEMBER 2015 17:00 – 18:00
30
Organised by: LG Life Sciences
iNDuSTRy MiNi SyMPOSiA
aDvancIng DIabeteS treatment anD future Per-SPectIveS
xxxxxx
Bernard Hall08:30 – 09:00 Pre-symposium breakfast
Chair: Jiten Vora (UK)Host: Ramon Gomis (ES)
09:00 – 09:10 Welcome to Novo Nordisk symposium at EASD Ramon Gomis (ES)
09:10 – 09:20 Introduction and update on basal insulin therapy Jiten Vora (UK)
09:20 – 09:40 Opportunities from designer proteins Peter Kurtzhals (DK)
09:40 – 09:55 Clinical profiles of new long-acting insulins and insulin combination products Thomas Pieber (AT)
09:55 – 10:10 Improving efficacy without compromising the risk of hypoglycaemia Athena Philis-Tsimikas (US)
10:10 – 10.25 Flexibility in dose timing matching patient needs Luigi Meneghini (US)
10:25 – 10:55 Coffee break
10:55 – 11:10 Synergies of complementary drugs John Buse (US)
11:55 – 12:30 Panel discussion
MONDAy, 14 SEPTEMBER 2015 10:00 – 17:00
31
iNDuSTRy SyMPOSiA
Organised by: Novo Nordisk
32
iNDuSTRy MiNi SyMPOSiA
the metabolIc chaoS of lIPoDyStroPhy – fInDIng the orDer wIthIn
Hodgkin HallKeynote speaker: Prof. Abhimanyu Garg (USA)
17:00 – 17:05 Welcome and introduction
17:05 – 17:45 Keynote speech Prof. Abhimanyu Garg (USA)
17:45 – 18:00 Questions and Answers
MONDAy, 14 SEPTEMBER 2015 17:00 – 18:00
Organised by: Aegerion
33
iNDuSTRy MiNi SyMPOSiA
challengeS In comPrehenSIve lIPID management
Pirart Hall
17:00 – 17:05 Welcome & Objectives
17:05 – 17:20 Cardiovascular Risk in Diabetes Patients: Just About Lipid Modification? Peter J. Grant (United Kingdom)
17:20 – 17:35 Dyslipidemia and Atherogenicity in T2DM: Looking Beyond the Obvious Alberto Zambon (Italy)
17:35 – 17:50 What is the Role of CETP in Lipid Metabolism? José María Mostaza Prieto (Spain)
17:50 – 18:00 Expert Panel
MONDAy, 14 SEPTEMBER 2015 17:00 – 18:00
Organised by: Eli Lilly and Company
34
iNDuSTRy MiNi SyMPOSiA
34
INDUSTRY PRogRammeSaVe THe DaTe
12 – 16 September 2016munich
on the occasion of the
52nd annual meeting of the european association
for the Study of Diabetes
INTERPLANmedia & service gmbh
www.easd-industry.com
12 September 2016
13 – 15 September 2016
15 September 2015
Industry Symposia & Industry mini Symposia
Industry exhibition
Industry evening Symposia
35
glP-1 recePtor agonIStS: lIraglutIDe 3.0 mg In weIght management
Loubatière Hall19:00 – 19:05 Welcome and introduction Joanna Uddén Hemmingsson (Sweden)
19:05 – 19:20 The role of GLP-1 in weight management: targeting central nervous system appetite regulation Darleen Sandoval (USA)
19:20 – 19:35 Optimising the dose for weight management: phase 2 results Nick Finer (UK)
19:35 – 20:00 SCALE Obesity and Prediabetes & SCALE Maintenance: key results Carel Le Roux (Ireland)
20:00 – 20:15 SCALE Diabetes: key results Tina Vilsbøll (Denmark)
20:15 – 20:30 Panel discussion All faculty
THURSDAy, 17 SEPTEMBER 2015 19:00 – 20:30
Organised by: Novo Nordisk
iNDuSTRy EvENiNg SyMPOSiA
emPa-reg outcome®: ImPlIcatIonS for management of PatIentS
wIth tyPe 2 DIabeteS
Meyer-Schwickerath Hall19:00 – 19:05 Welcome and introduction Lars Rydén (Sweden)
19:05 – 19:40 Exploring the results of EMPA-REG OUTCOME® Bernard Zinman (Canada)
19:40 – 20:20 Treatment of Type 2 Diabetes and cardiovascular risk in the context of EMPA-REG OUTCOME® Lars Rydén (Sweden)
Sanjay Kaul (USA)
Lawrence Leiter (Canada)
Naveed Sattar (UK)
20:20 – 20:30 Conclusion, summary and close Lars Rydén (Sweden)
THURSDAy, 17 SEPTEMBER 2015 19:00 – 20:30
36
iNDuSTRy EvENiNg SyMPOSiA
Organised by: Boehringer Ingelheim & Eli Lilly and Company
37
THIS ADVERTISEMENT PREPARED BY AREA23 Sig Date Time Time Spent Spell Check
Mac Op
QC
Editing
Copywriting
Art Director
Art Buying
Account
Traffic
Production
DQC
Client: BIProduct: Jardiance Global +EmpaMetJob#: 10361144Colors: 4C Sizes: Bleed: 216mm x 303mm
Sm Trim: 210mm x 297mmLive: 190mm x 277mmgutter: .375”
Publications:
A Size
It’s a pill with benefi ts I could appreciate?
TO
THAT
DOCTORSPEAKS
It’s a pill with benefi ts I could appreciate?Find out more at Booths
B10:21 and B10:20
Now those are benefi ts your patients could appreciate.
Issued June, 2015
Jardiance (empaglifl ozin) 10 mg, 25 mg fi lm-coated tablets, prescription only SGLT2 inhibitor.
Therapeutic indications:Jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as monotherapy: when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; add-on combination therapy: in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
Contraindications:Hypersensitivity to the active substance or any of the excipients.
Special warnings and precautions for use: Should not be used in patients with type 1 diabetes or diabetic ketoacidosis; patients with ESRD or in patients with dialysis; should not be initiated in patients with eGFR below 60 mL/min/1.73 m2; caution should be exercised in patients with a risk for volume depletion, such as patients aged 75 years or older, those on anti-hypertensive therapy with a
history of hypotension, with well known cardiovascular disease. In patients tolerating empaglifl ozin whose eGFR falls persistently below 60 mL/min/1.73 m2
or CrCl below 60 mL/min, the dose of empaglifl ozin should be adjusted to or maintained at 10 mg once daily. Empaglifl ozin should be discontinued when eGFR is persistently below 45 mL/min/1.73 m2 or CrCl persistently below 45 mL/min.
This drug is subject to additional monitoring. HCPs are asked to report any suspected adverse reactions.
May, 2014
MARKETINGAUTHORISATION HOLDERBoehringer Ingelheim International GmbH, Binger Str. 173, D-55216 Ingelheim am Rhein, Germany.
Further information on warnings and precautions on the use, interactions with other medical products and contraindications can be found in the Summary of Product Characteristics.
This is the prescribing information approved for use in Sweden. Please refer to your local prescribing information as this information may vary from country to country.
Synjardy (empaglifl ozin/metformin hydrochloride), fi lm-coated tablets, prescription only.
Synjardy 5 mg/850 mg. Each tablet contains 5 mg empaglifl ozin and 850 mg metformin hydrochloride.Synjardy 5 mg/1,000 mg. Each tablet contains 5 mg empaglifl ozin and 1,000 mg metformin hydrochloride.Synjardy 12.5 mg/850 mg. Each tablet contains 12.5 mg empaglifl ozin and 850 mg metformin hydrochloride.Synjardy 12.5 mg/1,000 mg. Each tablet contains 12.5 mg empaglifl ozin and 1,000 mg metformin hydrochloride.
SGLT2 inhibitor/Biguanide.Therapeutic indications:Synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximally tolerated dose of metformin alone, in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin, in patients already being treated with the combinationof empaglifl ozin and metformin as separate tablets.
Contraindications:Diabetic ketoacidosis, diabetic pre- coma, renal failure or renal dysfunction (creatinine clearance <60 mL/min), acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock. Acute or chronic disease which may cause tissue hypoxia such as: cardiac or respiratory failure, recent myocardial infarction, shock. Hepatic impairment, acute alcohol intoxication, alcoholism.
This drug is subject to additional monitoring. HCPs are asked to report any suspected adverse reactions.
June, 2015
MARKETING AUTHORISATION HOLDERBoehringer Ingelheim International GmbH, Binger Str. 173, D-55216 Ingelheim am Rhein, Germany.
Further information on warnings and precautions on the use, interactions with other medical products and contraindications can be found in the Summary of Product Characteristics.
This is the prescribing information approved for use in Sweden. Please refer to your local prescribing information as this information may vary from country to country.
• Signifi cant HbA1c reduction with the additional benefi t of weight loss2-5*†
• Effi cacy when added to a range of background treatments, including insulin3-5
• Convenient once-daily oral dosing
SYNJARDY, a new SGLT2 inhibitor + metformin combination therapy for adults with type 2 diabetes, provides6:
JARDIANCE, an SGLT2 inhibitor for adults with type 2 diabetes, provides1:
• The effi cacy of both empaglifl ozin and metformin in 1 pill6*†
• Flexible dosing options to individualise treatment6
• The convenience of a single-pill combination for your patients
*JARDIANCE and SYNJARDY are not indicated for weight loss. † Weight change was a secondary endpoint in clinical trials.
References: 1. JARDIANCE [summary of product characteristics]. Ingelheim am Rhein, Germany: Boehringer Ingelheim Pharmaceuticals, GmbH; 2014. 2. Roden M et al. Lancet Diabetes Endocrinol. 2013;1:208-219. 3. Häring HU et al. Diabetes Care. 2014;37:1650-1659. 4. Häring HU et al. Diabetes Care. 2013;36:3396–3404. 5. Rosenstock J et al. Poster presented at 49th Annual Meeting of the European Association for the Study of Diabetes; Sept. 23–27, 2013; Barcelona, Spain. 6. SYNJARDY [summary of product characteristics]. Ingelheim am Rhein, Germany: Boehringer Ingelheim Pharmaceuticals, GmbH; 2015.
To learn more about JARDIANCE and SYNJARDY,please contact your local representative.
Please see full Prescribing Information for additional information.
10361144_Jard+EmpaMet_EASD_JournalAd_FR.indd 2 6/11/15 6:24 PM
38
iNDuSTRy EvENiNg SyMPOSiA
the tecoS cv Safety trIal anD the leSSonS learneD for treatment of PatIentS wIth
tyPe 2 DIabeteS anD carDIovaScular DISeaSe
Kimmelstiel HallCo-Chairs: Niko Marx (Germany)
Juris Meier (Germany)
19:00 – 19:05 Welcome Niko Marx (Germany) and Juris Meier (Germany)
19:05 – 19:20 Continuing our Understanding of the Role DPP-4 Inhibitors Play in the Cardiovascular Patient with Type 2 Diabetes Richard Gilbert (Canada)
19:20 – 19:30 Q and A
19:30 – 19:55 TECOS CV SAFETy TRIAL: New Data from the CV Safety Trial for Sitagliptin Rury Holman (UK)
19:55 – 20:05 Q and A
20:05 – 20:25 Faculty Specialty Dialogue: Lessons Learned for the Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease All faculty
20:25 – 20:30 Closing Comments Niko Marx (Germany) and Juris Meier (Germany)
THURSDAy, 17 SEPTEMBER 2015 19:00 – 20:30
Organised by: Merck Sharp & Dohme
39
iNDuSTRy EvENiNg SyMPOSiA
the PatIent In mInD: new PerSPectIveS on Injectable theraPy
for tyPe 2 DIabeteS
Elite Hotel Marina TowerChair: Michael Nauck (Germany)
19:00 – 19:05 Introduction/Opening Michael Nauck (Germany)
19:05 – 19:25 Understanding the T2DM patient transition to injectable therapy Melanie Davies (UK)
19:25 – 19:45 What drives treatment persistence and preference in T2DM? Francesco Giorgino (Italy)
19:45 – 20:10 Can weekly GLP-1 RAs influence the current perspective of injectable therapies? A commentary on the latest data Michael Nauck (Germany)
20:10 – 20:30 Panel discussion + Wrap up Michael Nauck (Germany)
Please note this meeting is by registration only.
Please contact Lilly staff for further details.
THURSDAy, 17 SEPTEMBER 2015 19:00 – 20:30
Organised by: Eli Lilly and Company
iNDuSTRy EvENiNg SyMPOSiA
fOR fuRThER DETAiLS, PLEASE CONTACTINTERPLAN
Congress, Meeting & Event Management AG
Landsberger Str. 155
80687 Munich, Germany
Phone: +49 89 - 54 82 34-9055
Email: hotels2016@interplan.de
fiND yOuR PERfECT PLACE TO STAy iN MuNiCh!
The hotel capacities are limited and it is recommended to arrange your booking early.
http://hotels2016.easd-industry.com/
Username hotels2016Password Munich*16
41
BADgES DuRiNg SyMPOSiA DAyS
Due to safety reasons, the entrance to the conference site during the industry symposia on the occasion of the 51st EASD Annual Meeting will be strictly controlled.
This means that each regular attendee of the symposia day has to be identified as authorised by wearing a badge.
Our security staff will accept the following types of badges or name labels only:
• Regular delegate badge
• Regular exhibitor badge
• Special name tags, provided by the company itself, showing the status of the person wearing: “Invited by …, Guest of …, Technician of…“
Type of DelegateType of Badge
Access to Industry
Symposia 14.09.15
Access to the Scientific Sessions
15.– 18.09.15
Access to Industry Evening
Symposia 17.09.15
Access to the Industry
Exhibition 15.– 17.09.15
Speaker / Delegate registered for the Scientific Programme of the EASD Annual Meeting
Congress Badge ✔ ✔ ✔ ✔
Speaker / Delegate registered as an exhibitor for the Industry Exhibition of the EASD Annual Meeting
Exhibitor Badge ✔ ✘ ✔ ✔
Company Speaker / Delegate not registered for the EASD Annual Meeting
Own Company created Badge
✔ ✘ ✘ ✘
42
iMPRiNT
c/o INTERPLAN AGLandsberger Strasse 15580687 MunichGermany
Phone: +49 (0) 89 54 82 34-67Fax: +49 (0) 89 54 82 34-45Email: easd2015@interplan.deWebsite: www.interplan.de
Picture on page 7: © Stockholmsmässan, Karl GaborEach company is responsible for the content of their symposium.Status: July 2015. All subjects to change.
INTERPLANmedia & service gmbh
ABASAGLAR 100 units/mL solution for injection (insulin glargine)Cartridge, pre-filled pen (KwikPen™)
This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.
ATC code: A10AE04Drugs used in diabetes. Insulins and analogues for injection, long-acting.
Indications: Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.Contraindications: Hypersensitivity to the active substance or to any of the excipients.Warnings: ABASAGLAR is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously is recommended in such cases. In case of insufficient glucose control or a tendency to hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, long acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose. Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.Date of revision of the text: 17 February 2015 For further information and prices see www.fass.seRx, not FThis text is based on the Swedish prescribing information. Please contact your local Lilly representative for information relevant to your country.
Eli Lilly Sweden AB, Box 721, 169 27 Solna. 08-737 88 00. www.lilly.se.
Date of last SmPC update: 2015-04-16
LET’S TALK ABOUT helping your patients feel better about starting basal insulin.Introducing ABASAGLAR—a once-daily insulin glargine with clinical benefits you may
find familiar and an initiation experience your patients may find appealing.
Visit Lilly booth B10:20 and BI booth B10:21 to learn more.
SEDBT01535 02-JUN-2015
THIS ADVERTISEMENT PREPARED BY AREA23 Sig Date Time Time Spent Spell Check
Mac Op
QC
Editing
Copywriting
Art Director
Art Buying
Account
Traffic
Production
DQC
Client: BI Product: Basaglar Job#: 10347992Colors: 4C Sizes: Bleed: 213mm x 300mm
Trim: 210mm x 297mm Live: 209mm x 296mm gutter: N/A
Publications:
A Size
10347992_EASD_Journal_Ad_FR.indd 1 6/4/15 11:45 AM
Join us at this state-of-the-art symposium and be one of the first to discuss the results of the EMPA-REG OUTCOME™ trial with leading experts
EMPA-REG O
UTCOME™:
Impl
icatio
ns fo
r man
agem
ent
of pa
tient
s with
Type
2 Diab
etes
17 S
epte
mbe
r 201
5, 19
:00–
20:3
0; C
hair:
Lar
s Ryd
én
Mey
er-S
chwick
erat
h Hal
l, Sto
ckho
lm In
tern
ation
al Fa
irs an
d Con
gres
s Cen
tre, S
weden
Lars R
ydén
(Swed
en)
Lars R
ydén
(Swed
en)
Lars R
ydén
(Swed
en)
Sanja
y Kau
l (USA
)Law
rence
Lei
ter (
Canad
a)
Navee
d Sat
tar (
UK)
Bernar
d Zinm
an (C
anad
a)
Bernar
d Zinm
an (C
anad
a)
19:0
0
19:0
5
19:4
0
20:2
0
Wel
com
e and in
troduct
ion
Explo
ring th
e res
ults
of E
MPA-R
EG OUTCOM
E™
Concl
usion, s
umm
ary
and cl
ose
Trea
tmen
t of T
ype 2
Dia
betes
and
card
iova
scula
r risk
in th
e con
text
of E
MPA-R
EG OUTCOM
E™
Panel
disc
ussio
n
Audi
ence
Q&A
D0394 Empa-REG Symposia Ad_A4 S05.indd 1 05/06/2015 08:52
top related